Novavax Phase 1/2a H5N1 vaccine results published
Safety, immunogenicity and cross-reactivity results from a Phase 1/2a clinical study by Novavax (NASDAQ:NVAX) of its H5N1 influenza virus-like particle (VLP) vaccine candidate were published in the current issue of Journal of Virology.
Novavax’s VLP-based vaccine targeted against a highly pathogenic avian H5N1 influenza virus was well-tolerated, produced no vaccine-related serious adverse events and induced neutralizing antibodies that were cross-reactive with different avian A/H5N1 influenza viruses, according to the article.
This is the first report of a unadjuvanted vaccine inducing cross-reactive neutralizing antibodies against multiple clades of H5N1 influenza virus. “The antibodies induced by this vaccine candidate without the use of an adjuvant indicate that the VLP is immunogenic relative to egg-based or cell-culture-derived H5N1 vaccines,” CMO Dr. Greg Glenn said in a statement.
Transmission of the highly pathogenic avian H5N1 flu virus in domestic poultry and humans is continuing in many countries and remains a serious pandemic threat with the potential to evolve into new strains where cross-protection and induction of neutralizing antibodies will be essential.